The glucagon-like peptide-1 receptor agonist diabetes medications have become important due to their unique features, such as their potency of glycosylated hemoglobin (HbA1C) lowering, durability of effect, glucose-depending insulin secretion resulting in a low risk of hypoglycemia, glucagon suppression, and weight loss. Lixisenatide is an investigational compound in this class, exhibits all of these features, and has some unique properties, which are highlighted in this review. The pharmacology of lixisenatide, the results of recent clinical trials investigating this agent, and its potential role in the management of type 2 diabetes will be discussed.
|Original language||English (US)|
|Number of pages||6|
|State||Published - Dec 2011|
- Glucagon-like peptide-1 receptor agonist
- Type 2 diabetes
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism